Morbidity and Function Loss After Resection of Malignant Peripheral Nerve Sheath Tumors.
Journal
Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
accepted:
16
07
2021
received:
23
12
2020
pubmed:
17
9
2021
medline:
22
7
2022
entrez:
16
9
2021
Statut:
ppublish
Résumé
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas. Their resection may lead to serious morbidity. Incidence of postoperative motor and sensory deficits is unknown, and reconstruction aimed at restoring such deficits is infrequently carried out. To identify the incidence and risk factors of postoperative morbidity in MPNST as well as the use and outcomes of functional reconstructions in these patients. Postoperative function and treatment of MPNSTs diagnosed from 1988 to 2019 in 10 cancer centers was obtained. Two models were constructed evaluating factors independently associated with postoperative motor (<M3) or critical sensory loss. Critical sensation was defined as partial or complete loss of hand, foot, or buttocks sensation. A total of 756 patients (33.4% neurofibromatosis type 1, NF1) were included. MPNSTs originated in 34.4% from a major nerve. Of 658 surgically treated patients, 27.2% had <M3 muscle power and 24.3% critical sensory loss. Amputations were carried out in 61 patients. Independent risk factors for motor and sensory loss included patients with NF1, symptomatic, deep-seated, extremity, or plexus tumors originating from major nerves (all P < .05). A total of 26 patients underwent functional reconstructions. The majority (64%) of these patients regained at least M3 muscle power and 33% M4 despite 86% receiving multimodal therapy. Resection of MPNSTs commonly results in motor and sensory deficits. Patients with NF1, symptomatic, deep-seated tumors, arising from major nerves were associated with a higher risk for developing postoperative morbidity. Functional reconstructions are infrequently performed but can improve functional outcomes.
Sections du résumé
BACKGROUND
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas. Their resection may lead to serious morbidity. Incidence of postoperative motor and sensory deficits is unknown, and reconstruction aimed at restoring such deficits is infrequently carried out.
OBJECTIVE
To identify the incidence and risk factors of postoperative morbidity in MPNST as well as the use and outcomes of functional reconstructions in these patients.
METHODS
Postoperative function and treatment of MPNSTs diagnosed from 1988 to 2019 in 10 cancer centers was obtained. Two models were constructed evaluating factors independently associated with postoperative motor (<M3) or critical sensory loss. Critical sensation was defined as partial or complete loss of hand, foot, or buttocks sensation.
RESULTS
A total of 756 patients (33.4% neurofibromatosis type 1, NF1) were included. MPNSTs originated in 34.4% from a major nerve. Of 658 surgically treated patients, 27.2% had <M3 muscle power and 24.3% critical sensory loss. Amputations were carried out in 61 patients. Independent risk factors for motor and sensory loss included patients with NF1, symptomatic, deep-seated, extremity, or plexus tumors originating from major nerves (all P < .05). A total of 26 patients underwent functional reconstructions. The majority (64%) of these patients regained at least M3 muscle power and 33% M4 despite 86% receiving multimodal therapy.
CONCLUSION
Resection of MPNSTs commonly results in motor and sensory deficits. Patients with NF1, symptomatic, deep-seated tumors, arising from major nerves were associated with a higher risk for developing postoperative morbidity. Functional reconstructions are infrequently performed but can improve functional outcomes.
Identifiants
pubmed: 34528095
pii: 00006123-202203000-00014
doi: 10.1093/neuros/nyab342
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
354-364Informations de copyright
Copyright © Congress of Neurological Surgeons 2021. All rights reserved.
Références
Ng VY, Scharschmidt TJ, Mayerson JL, Fisher JL. Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer Res. 2013;33(6):2597-2604.
Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107(5):1065-1074.
Martin E, Coert JH, Flucke UE, et al. A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer. 2020;124:77-87.
Miao R, Wang H, Jacobson A, et al. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol. 2019;137:61-70.
Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016;56:77-84.
von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(6):758-786.
Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020;38(19):2178-2186.
Higham CS, Steinberg SM, Dombi E, et al. SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors. Sarcoma. 2017;2017:1-8.
Davis AM, Sennik S, Griffin AM, et al. Predictors of functional outcomes following limb salvage surgery for lower-extremity soft tissue sarcoma. J Surg Oncol. 2000;73(4):206-211.
Davis AM, Bell RS, Badley EM, Yoshida K, Williams JI. Evaluating functional outcome in patients with lower extremity sarcoma. Clin Orthop Relat Res. 1999;358:90-100.
Mundinger GS, Prucz RB, Frassica FJ, Deune EG. Concomitant upper extremity soft tissue sarcoma limb-sparing resection and functional reconstruction: assessment of outcomes and costs of surgery. Hand. 2014;9(2):196-204.
Saint-Cyr M, Langstein HN. Reconstruction of the hand and upper extremity after tumor resection. J Surg Oncol. 2006;94(6):490-503.
Martin E, Dullaart MJ, van de Sande MAJ, van Houdt WJ, Schellekens PPA, Coert JH. Resuscitating extremities after soft tissue sarcoma resections: are functional reconstructions an overlooked option in limb salvage? A systematic review. Eur J Surg Oncol. 2019;45(10):1762-1769.
Martin E, Dullaart MJ, Verhoef C, Coert JH. A systematic review of functional outcomes after nerve reconstruction in extremity soft tissue sarcomas: a need for general implementation in the armamentarium. J Plast Reconstr Aesthet Surg. 2020;73(4):621-632.
Jones KB, Ferguson PC, Deheshi B, et al. Complete femoral nerve resection with soft tissue sarcoma: functional outcomes. Ann Surg Oncol. 2010;17(2):401-406.
Alamanda VK, Crosby SN, Archer KR, Song Y, Schwartz HS, Holt GE. Amputation for extremity soft tissue sarcoma does not increase overall survival: a retrospective cohort study. Eur J Surg Oncol. 2012;38(12):1178-1183.
Ghert MA, Abudu A, Driver N, et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol. 2005;12(1):10-17.
Casali PG, Abecassis N, Aro HT, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv51-iv67.
Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62(5):1573-1577.
Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42(2):351-360.
Zehou O, Fabre E, Zelek L, et al. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis. 2013;8(1):127.
Gerrand CH, Wunder JS, Kandel RA, et al. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br. 2001;83(8):1149-1155.
Clarkson PW, Griffin AM, Catton CN, et al. Epineural dissection is a safe technique that facilitates limb salvage surgery. Clin Orthop Relat Res. 2005;438:92-96.
Stucky C-CH, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19(3):878-885.
Martin E, Slooff W-BM, van Houdt WJ, van Dalen T, Verhoef C, Coert JH. Oncological treatment considerations differ across surgical subspecialties treating malignant peripheral nerve sheath tumors: an international survey. Sarcoma. 2020;2020:6406439.
Martin E, Coert JH, Flucke UE, et al. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: a nationwide cohort study. Pediatr Blood Cancer. 2020;67(4):e28138.
van Noesel MM, Orbach D, Brennan B, et al. Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: an analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. Pediatr Blood Cancer. 2019;66(10):e27833.
Dunn GP, Spiliopoulos K, Plotkin SR, et al. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1: clinical article. J Neurosurg. 2013;118(1):142-148.
Nambisan RN, Rao U, Moore R, Karakousis CP. Malignant soft tissue tumors of nerve sheath origin. J Surg Oncol. 1984;25(4):268-272.
Melendez M, Brandt K, Evans GR. Sciatic nerve reconstruction: limb preservation after sarcoma resection. Ann Plast Surg. 2001;46(4):375-381.
Tokumoto H, Akita S, Kubota Y, Kuriyama M, Mitsukawa N. Use of vascularized sural nerve grafts for sciatic nerve reconstruction after malignant bone and soft tissue tumor resection in the lower legs. Ann Plast Surg. 2018;80(4):379-383.
Marsden N, Grinsell D. Advances in functional limb reconstruction in the irradiated setting. Plast Aesthetic Res. 2019;6:24.
Eberlin KR, Ducic I. Surgical algorithm for neuroma management: a changing treatment paradigm. Plast Reconstr Surgery Glob Open. 2018;6(10):e1952.
Brandt K, Evans GR, Johnson M, et al. The effects of cisplatinum and vincristine on peripheral nerve regeneration. Plast Reconstr Surg. 1999;104(2):464-469.
Brandt K, Evans GR, Ang KK, et al. Postoperative irradiation: are there long-term effects on nerve regeneration? J Reconstr Microsurg. 1999;15(6):421-425.
Brandt K, Evans GR, Gurlek A, et al. The effects of preoperative irradiation on peripheral nerve regeneration. Ann Plast Surg. 1998;40(3):277-282.
Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249(6):1014-1022.
Puffer RC, Marek T, Stone JJ, Raghunathan A, Howe BM, Spinner RJ. Extensive perineural spread of an intrapelvic sciatic malignant peripheral nerve sheath tumor: a case report. Acta Neurochir. 2018;160(9):1833-1836.
Sanniec KJ, Velazco CS, Bryant LA, et al. Immediate versus delayed sarcoma reconstruction: impact on outcomes. Sarcoma. 2016;2016:1-5.
Marre D, Buendia J, Hontanilla B. Complications following reconstruction of soft-tissue sarcoma: importance of early participation of the plastic surgeon. Ann Plast Surg. 2012;69(1):73-78.
Reece GP, Schusterman MA, Pollock RE, et al. Immediate versus delayed free-tissue transfer salvage of the lower extremity in soft tissue sarcoma patients. Ann Surg Oncol. 1994;1(1):11-17.